Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and non-childbearing female subjects (SAD/MAD) and male and non-childbearing female patients with mild asthma;~* Healthy subjects as determined by past medical history, vitals, physical examination and 12-lead ECG, clinical laboratory tests.~* Body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive, weight ≥50 kg;~* Non-smokers or ex-smokers~* Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the subject; able to comply with protocol requirements and or study procedure;~* Negative screen for drugs of abuse and alcohol at screening and on admission.~* Male subjects should agree not to donate sperm for 3 months post dose; and~* Female partners (of child bearing potential) of male subjects should use 2 methods of highly effective contraception for 3 months post last~Additionally for POC~* Pre- bronchodilator Forced expiratory volume in 1 sec( FEV1) of \> 70% (adjusted for age, sex and race)~* Steroid naïve subjects with history of mild asthma that satisfy the Global Initiative for Asthma (GINA) definition of asthma, but otherwise healthy.~Exclusion Criteria:~* Subjects with evidence or history of clinically significant medical history.~* History of tuberculosis (TB) and/or a positive Tuberculin Skin Test and/or QuantiFeron- TB®-Gold test.~* Use of any immunotherapy within 3 months prior to screening.~* History of serious adverse reaction, severe hypersensitivity or allergy to any drug/drug substance (except house dust mite, pollen allergens or cat dander allergy in asthmatics) or in any other circumstance (e.g. anaphylaxis);~* Abnormal liver function~* Positive screen on hepatitis-B surface antigen (HBsAg), antibodies to the hepatitis C (HCV) or antibodies to the human immunodeficiency virus (HIV) 1,2;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- RP3128 (Type: EXPERIMENTAL): RP3128, A CRAC channel modulator
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).